Integrated Direct-to-Biology (D2B) Platform

Looking for a solution to accelerate your drug discovery processes? Introducing WuXi AppTec’s Integrated Direct-to-Biology (D2B) platform—a cost-effective and time-saving approach that empowers small molecule and peptide optimization, rapid SAR exploration, and the discovery of targeted protein degraders.

The WuXi AppTec D2B platform integrates the expertise of medicinal chemistry, high-throughput synthesis and assays, and computer-aided drug design, streamlining iterative design-synthesis-test cycles by directly testing high-throughput synthesized compounds in biological assays. Starting from a primary hit or ligand, our D2B platform enables rapid go/no-go decisions and hit triage, resulting in more efficient research outcomes with a typical timeline of just 2 – 3 weeks per cycle.